India is strengthening regulatory oversight across its pharmaceutical sector. Since December 2022, CDSCO and State Drugs Controllers have conducted more than 960 risk-based inspections, leading to over 860 regulatory actions. Therefore, pharmaceutical professionals need a clear understanding of pharmaceutical legislation in India to manage compliance and reduce regulatory risk. In addition, pharma legislation affects drug approvals, manufacturing licences, clinical trials, GMP compliance, and inspections. This guide explains the key rules, authorities, and requirements that professionals need to understand in 2026.
Table of Contents
What Is Pharmaceutical Legislation in India?
Pharmaceutical legislation in India includes the laws, rules, regulators, and enforcement systems that control medicines throughout their lifecycle. It covers areas such as drug approval, manufacturing, import, distribution, clinical trials, labelling, and quality compliance. In addition, regulators use inspections, licensing actions, testing, and legal enforcement to monitor compliance. Therefore, pharmaceutical professionals must understand both the legal framework and the practical controls that apply to their products and operations.
How Drug Regulations in India Become Inspection Requirements
Drug regulations in India do more than set legal expectations. They directly shape licensing, GMP controls, documentation, sampling, and inspection practices. For example, manufacturers must translate regulatory requirements into approved procedures, controlled records, qualified systems, and trained activities. In addition, inspectors use these requirements to assess whether a facility consistently meets its legal and quality obligations. Therefore, strong regulatory understanding helps pharmaceutical teams prepare for inspections, reduce compliance gaps, and maintain an effective state of control.
Core Regulatory Controls for Pharmaceutical Compliance in India
Together, these four regulatory areas show how Indian pharmaceutical requirements move from legal obligations to quality systems, product approvals, licensing controls, and inspection evidence.
The following four regulatory areas are central to pharmaceutical compliance in India:
- Drugs and Cosmetics Act and Licensing Controls (PDF)
- Revised Schedule M and Pharmaceutical Quality Systems (PDF)
- New Drug Approval Under NDCTR (PDF)
- Risk-Based GMP Inspections by CDSCO (PDF)
Drugs and Cosmetics Act and Licensing Controls (PDF)
The Act and Rules govern drug manufacturing, sale, distribution, and licensing in India. Manufacturers must meet licence conditions, documentation, testing, facility, and inspection requirements.
Revised Schedule M and Pharmaceutical Quality Systems (PDF)
Revised Schedule M strengthens GMP through pharmaceutical quality systems, risk management, validation, change control, and product quality review. Companies must maintain clear evidence that these systems work effectively.
Download Update on Drugs & Cosmetics Act and Revised Schedule M: 28 June 2024 Here
The infographic below shows how revised Schedule M turns core quality-system requirements into practical, inspection-ready GMP evidence.
New Drug Approval Under NDCTR (PDF)
NDCTR 2019 defines requirements for clinical trials and new drug approvals in India. Sponsors must submit the required applications, safety data, clinical evidence, and regulatory documentation to CDSCO.
Risk-Based GMP Inspections by CDSCO (PDF)
CDSCO uses risk-based inspections to focus regulatory attention on higher-risk manufacturing sites and products. Inspection outcomes can lead to observations, corrective actions, licence-related measures, and further regulatory follow-up.
Download Guidance Document for Risk Based Inspection of Drug Manufacturing Sites Here
The infographic below shows how CDSCO risk-based inspections move from site-risk signals to GMP review, evidence assessment, and final finding classification.
Who Regulates What in India: CDSCO and State Drug Authorities?
India uses a shared regulatory system rather than one authority for every pharmaceutical activity. CDSCO manages key central functions, including new drug approvals, clinical trials, drug imports, national standards, and coordination between states. Meanwhile, State Drug Authorities primarily regulate manufacturing, sale, and distribution within their jurisdictions. Therefore, pharmaceutical companies often need to manage both central and state requirements to maintain approval, licensing, GMP compliance, and inspection readiness.
The table below shows how major pharmaceutical regulatory responsibilities are divided between CDSCO and State Drug Authorities.
| Regulatory Area | CDSCO / Central Authority | State Drug Authorities | Practical Impact |
|---|---|---|---|
|
New Drug Approval |
Reviews and approves new drugs under central regulations. |
Support local implementation and oversight where applicable. |
Companies need central approval before marketing qualifying new drugs. |
|
Clinical Trials |
Authorizes regulated clinical trials and related applications. |
Support local oversight and enforcement activities. |
Sponsors must meet CDSCO and NDCTR requirements before starting trials. |
|
Manufacturing Licences |
Handles specified central licensing functions. |
Primarily issue and manage manufacturing licences. |
Manufacturers must obtain the correct licence before production. |
|
GMP Inspections |
Conducts or participates in central and risk-based inspections. |
Inspect licensed manufacturing sites for GMP compliance. |
Facilities should remain ready for both central and state inspections. |
|
Enforcement |
Coordinates national regulatory actions and compliance standards. |
Investigate violations and may initiate legal action. |
Serious non-compliance can lead to suspension, prosecution, or other regulatory measures. |
The division is not absolute. For example, CDSCO also has licensing responsibilities for specified drug categories, while central and state regulators may work together during inspections and enforcement activities. Official CDSCO guidance confirms that states primarily regulate manufacture, sale, and distribution, while central authorities oversee areas such as new drugs, clinical trials, imports, standards, and nationwide regulatory coordination.
What Changed for Indian Pharma Compliance?
Indian pharma compliance is becoming more structured, digital, and risk-focused. Recent CDSCO developments include implementation of pharmacovigilance requirements under Schedule M, revised regulatory guidance for drug sampling, and expanded use of online regulatory submissions. Therefore, pharmaceutical companies should review their quality systems, safety monitoring, documentation, sampling procedures, and regulatory workflows. In addition, teams should track new CDSCO notifications closely because even small procedural changes can affect inspection readiness and ongoing compliance.
Final Words
India’s inspection environment is becoming more targeted and risk-focused. In fact, regulators have subjected more than 1,100 cough syrup manufacturers to intensive audits, showing how quickly quality concerns can trigger focused oversight. Therefore, companies should treat pharmaceutical legislation in India as an active compliance framework, not simply a legal reference. Strong quality systems, reliable documentation, and continuous inspection readiness will remain essential as regulatory scrutiny increases.
Quality Management System
We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.
FAQ
CDSCO inspectors assess compliance with applicable GMP requirements, including facilities, quality systems, documentation, manufacturing controls, laboratory practices, validation, and product-quality controls. Revised Schedule M has strengthened these expectations for Indian drug manufacturers.
CDSCO may prioritize sites based on factors such as Not of Standard Quality results, complaints, product criticality, compliance history, recalls, and potential patient risk. Therefore, sites with stronger risk signals can receive greater regulatory attention.
Serious inspection findings can lead to show-cause notices, stop-production orders, warnings, licence suspension, or licence cancellation, depending on the severity of the deficiencies. Manufacturers may also need to correct identified quality-system gaps before normal operations continue.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.